News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Etubics Presents "Next Generation" Of Adenovirus Vaccine At Annual Aids Vaccine Conference


9/27/2010 1:40:15 PM

SEATTLE (September 27, 2010) – Etubics Corporation will report on a novel "next generation" therapeutic adenovirus vaccine platform at the AIDS Vaccine Conference at the Omni Hotel at CNN Center in Atlanta, Ga. in the International Ballroom from 3 p.m. to 4 p.m. on Thursday, September 30, 2010. Etubics' "next generation" adenovirus vector platform has been reported to allow for induction of robust immune responses to multiple transgene antigens in the presence of Ad5 immunity.

"Our non-human primate HIV vaccination data to be presented at this international HIV Conference is one step closer to an effective vaccine," said Dr. Frank R. Jones, founder, Chairman and Chief Executive Officer of Etubics. "Clinical studies at leading universities around the country will enhance our promise that Etubics' human cell based novel vector vaccine platform can overcome this issue for not just pandemic vaccines, but also therapeutic vaccines for hard to treat cancers and HIV."

Etubics will present their evaluation of the recombinant Gag, Pol and Nef HIV-1 viral vector vaccine in an Ad5 immune non-human primate model. Etubics has previously reported the use of the Ad5 [E1-, E2b-] platform to induce cellular immune responses (CMI) against HIV-1 Gag in Ad5 hyper immune mice as well as the successful induction of CMI against HIV-1 Gag, Pol, and Nef constructed in the Ad5 [E1-, E2b-] platform.

Etubics' utilized its "next generation" vector vaccine platform with their patented E.C7 human manufacturing cell line technology as a gene delivery vehicle that can be used to efficiently develop preventative and treatment vaccines against a wide range of infectious diseases and cancers. Pre-clinical trials of Etubics "next generation" vector vaccines have shown the proprietary adenovirus platform to have the following novel attributes:

• Stealth Like Vaccine Delivery. The additional genetic deletions in the Company’s novel vectors allow the vaccine platform to be delivered multiple times to the same patient without the vector immunity issues described above.

• Generates Cell-Mediated Immunity and Antibody Responses. Etubics believes that CMI responses may provide the greatest treatment value or protection from hard to treat diseases. Pre-clinical trials have shown that Etubics can induce CMI even in the presence of adenovirus immunity. Clinical trials are under way to confirm this in humans.

• Rapid Application for Emerging Diseases. Etubics can take a vaccine from identification of disease to clinical application within 6 to 12 months as our vaccines are created in human cell lines and are based off of our patented platform.

• Manufacturing Efficiency. Etubics can quickly and efficiently scale up production within months of regulatory clearance.

• Potential To Treat A Wide Range Of Diseases. Etubics vector vaccine candidates have one of the largest carrying capacities allowing the platform to work with a wide variety of diseases and obviating the need for a researcher to choose a portion of the disease to target.

Etubics is developing next generation vaccines, utilizing a patented advanced generation adenovirus vector delivery platform and a validated manufacturing human cell line, called E.C7. Etubics intends to develop vector vaccines for a variety of indications utilizing its platform technology, which has attributes that allow for broad transgene expression.

Etubics "next generation" vector vaccine platform has been researched in the scientific laboratory for more than 12 years. The Company is currently in clinical trials in the United States utilizing with their first vaccine candidate for the treatment of colon cancer.

About AIDS Vaccine Conference

AIDS Vaccine 2010 aims to help cultivate a global network of scientific talent to carry the field of HIV vaccine research into the future. Since the first conference, organized in Paris in 2000, the AIDS Vaccine conference has become one of the most important annual events for the exchange of scientific information relating to HIV vaccine research and development. Beginning in 2007, the annual conference is organized under the aegis of the Enterprise and contributes to the goals of the Enterprise by: providing a venue for an international exchange of information in HIV vaccine research and development; cross-fertilizing scientific areas of research; increasing coordination and communication among international groups; and monitoring progress in the field.

About Etubics

Etubics Corporation is a Seattle based biopharmaceutical company with technology that enables the rapid, cost-effective development and commercialization of therapeutic and preventative vaccines targeting hard to treat diseases. Etubics is currently in clinical trials with a colon cancer therapeutic vaccine. Led by an experienced scientific and management team, Etubics’ patented platform leverages the advantages of vector technology, while overcoming historical safety and re-immunization issues of earlier platforms. Etubics was established by Dr. Frank R. Jones and is currently engaged in research and development of its proprietary and novel adenovirus vector vaccine candidates. www.etubics.com.

Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’ product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of Etubics proposed candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.

Investor/Media contact: Kimberly Jones Phone: (206) 838-5110 Ext. 110 kimberly@etubics.com


Read at BioSpace.com

Related News

comments powered by Disqus
Etubics
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES